aTYR PHARMA (ATYR) Current Leases (2019 - 2026)
aTYR PHARMA's (ATYR) quarterly Current Leases came in at $946000.0 in Q2 2026, up 23.02% on a YoY basis from $769000.0 in Q2 2025, and up 6.29% quarter-over-quarter from $890000.0 in Q1 2026.
Powered by 
Analysis
aTYR PHARMA (ATYR) Current Leases (2019 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has reported Current Leases for 8 consecutive years, with $946000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Current Leases rose 23.02% year-over-year to $946000.0; the trailing twelve-month figure through Jun 2026 stood at $946000.0 (up 23.02% YoY), and the FY2025 full-year result was $836000.0, up 17.58% from the prior year.
- Current Leases climbed to $946000.0 in Q2 2026 per ATYR's latest filing, from $890000.0 in the prior quarter.
- Across five years, Current Leases topped out at $1.0 million in Q1 2022 and bottomed at $420000.0 in Q1 2023.
- Historically, Current Leases has averaged $750555.6 across 5 years, with a median of $754500.0 in 2025.
- The sharpest annual moves came in 2023 and 2024: Current Leases tumbled 58.5% in 2023, then jumped 49.76% in 2024.
- Over 5 years, Current Leases stood at $630000.0 in 2022, then jumped by 31.9% to $831000.0 in 2023, then fell by 14.44% to $711000.0 in 2024, then advanced by 17.58% to $836000.0 in 2025, then grew by 13.16% to $946000.0 in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $946000.0, $890000.0, and $836000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 720.00 Mn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | - |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 11.00 Mn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | 12.38 Mn |
| 10 | aTYR PHARMA | 35.31 Mn | -22.30 Mn | - | 946,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 946,000.00 |
| Mar 31, 2026 | 890,000.00 |
| Dec 31, 2025 | 836,000.00 |
| Sep 30, 2025 | 799,000.00 |
| Jun 30, 2025 | 769,000.00 |
| Mar 31, 2025 | 740,000.00 |
| Dec 31, 2024 | 711,000.00 |
| Sep 30, 2024 | 683,000.00 |
| Jun 30, 2024 | 656,000.00 |
| Mar 31, 2024 | 629,000.00 |
| Dec 31, 2023 | 831,000.00 |
| Sep 30, 2023 | 774,000.00 |
| Jun 30, 2023 | 621,000.00 |
| Mar 31, 2023 | 420,000.00 |
| Dec 31, 2022 | 630,000.00 |
| Sep 30, 2022 | 657,000.00 |
| Jun 30, 2022 | 906,000.00 |
| Mar 31, 2022 | 1.01 Mn |
| Dec 31, 2021 | 980,000.00 |
| Sep 30, 2021 | 949,000.00 |